We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID-19 Drug Discovery Using Intensive Approaches.
- Authors
Asai, Ayumu; Konno, Masamitsu; Ozaki, Miyuki; Otsuka, Chihiro; Vecchione, Andrea; Arai, Takahiro; Kitagawa, Toru; Ofusa, Ken; Yabumoto, Masami; Hirotsu, Takaaki; Taniguchi, Masateru; Eguchi, Hidetoshi; Doki, Yuichiro; Ishii, Hideshi
- Abstract
Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.
- Subjects
COVID-19; WORLD Health Organization; RNA virus infections; MIDDLE East respiratory syndrome; SARS disease; PANDEMICS; COMMUNICABLE diseases; RNA viruses
- Publication
International Journal of Molecular Sciences, 2020, Vol 21, Issue 8, p2839
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms21082839